| 35.49 -0.517 (-1.44%) | 03-02 13:19 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 44.02 | 1-year : | 51.41 |
| Resists | First : | 37.68 | Second : | 44.02 |
| Pivot price | 35.96  |
|||
| Supports | First : | 34.77  |
Second : | 32.97 |
| MAs | MA(5) : | 35.56 |
MA(20) : | 35.66 |
| MA(100) : | 31.29 |
MA(250) : | 0 | |
| MACD | MACD : | 0.7 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 31.5 |
D(3) : | 38 |
| RSI | RSI(14): 53.8 |
|||
| 52-week | High : | 38.35 | Low : | 25.35 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TBXU ] has closed above bottom band by 34.5%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 36.13 - 36.27 | 36.27 - 36.43 |
| Low: | 35.11 - 35.26 | 35.26 - 35.43 |
| Close: | 35.21 - 35.45 | 35.45 - 35.73 |
The fund seeks daily investment results (before fees and expenses) of 200% of the daily performance of the NYSE Biotechnology Top 5 Equal Weight Index.
Fri, 27 Feb 2026
Stock List: Research Stocks from Around the World - GuruFocus
Fri, 20 Feb 2026
TBXU | Direxion Daily Biotech Top Institutional Ownership - Quiver Quantitative
Fri, 23 Jan 2026
LABU: The Risks And Rewards Of A Leveraged Biotechnology ETF (NYSEARCA:LABU) - Seeking Alpha
Tue, 23 Dec 2025
Remember the Titans ETFs For Opportunities in 2026 - ETF Trends
Fri, 28 Nov 2025
Can Biotech’s Top 5 Revive the Sector’s Pulse? - Direxion
Thu, 02 Oct 2025
US ETF launches from 25th September to 2nd October, 2025 - ETF Express
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|